Bicycle Therapeutics plc

(NASDAQ:BCYC)

Latest On Bicycle Therapeutics plc (BCYC):

Date/Time Type Description Signal Details
2023-05-14 14:15 ESTNewsBicycle Therapeutics: Not Much Differentiation Between Bicycles And mAbs YetN/A
2023-05-10 11:38 ESTNewsBicycle stock jumps on pact with Bayer to develop radiopharmaceuticals for cancerN/A
2023-05-04 21:13 ESTNewsBicycle Therapeutics GAAP EPS of -$1.30, revenue of $4.89MN/A
2023-03-28 17:17 ESTNewsBicycle stock pops on cancer drug discovery pact with Novartis, gets $50M upfrontN/A
2023-02-28 15:09 ESTNewsBicycle Therapeutics GAAP EPS of -$1.01 beats by $0.05, revenue of $3.19M misses by $0.56MN/A
2023-02-14 18:15 ESTNewsBicycle Therapeutics posts Phase 1 data for cancer candidateN/A
2023-01-04 15:09 ESTNewsBicycle Therapeutics adds 10% on FDA’s fast track tag for bladder cancer therapyN/A
2022-11-03 21:35 ESTNewsBicycle Therapeutics GAAP EPS of -$0.96 misses by $0.05, revenue of $3.04M misses by $2.54MN/A
2022-10-08 01:53 ESTNewsBicycle Therapeutics: Exploring An Intriguing Developmental PlatformN/A
2022-09-01 00:39 ESTNewsBicycle Therapeutics initiated Outperform at Cowen citing drug platformN/A
2022-08-04 22:13 ESTNewsBicycle Therapeutics GAAP EPS of -$0.90 misses by $0.04, revenue of $4.38M beats by $0.69MN/A
2022-07-12 21:29 ESTNewsBicycle to get $10M as Genentech uses option for new program under cancer drug collaborationN/A
2022-07-06 01:28 ESTNewsBicycle Therapeutics: Promising Early-Stage Cancer Drug DeveloperN/A
2022-05-05 19:05 ESTNewsBicycle Therapeutics GAAP EPS of -$0.93 misses by $0.26, revenue of $3.86M misses by $0.55MN/A
2022-04-17 04:20 ESTNewsBicycle Therapeutics: Trying To Catch This Falling KnifeN/A
2022-04-11 15:59 ESTNewsBicycle Therapeutics down 33% after rising sharply on Friday on bladder cancer dataN/A
2022-04-11 15:59 ESTNewsBicycle Therapeutics presents at AACR Annual Meeting 2022 - SlideshowN/A
2022-04-09 02:28 ESTNewsBicycle Therapeutics gains on early-stage data for oncology asset in bladder cancerN/A
2022-03-27 00:04 ESTNewsBicycle Therapeutics: A Buy Ahead Of AACR PresentationN/A
2022-03-01 19:32 ESTNewsBicycle Therapeutics GAAP EPS of -$0.63 beats by $0.01, revenue of $3.77M misses by $1.11MN/A
2022-02-28 05:43 ESTNewsBicycle Therapeutics: An Oncology Play With Big PotentialN/A
2022-01-05 15:44 ESTNewsBicycle Therapeutics COO transitions to CTO; provides clinical program updatesN/A
2021-11-10 00:38 ESTNewsBicycle Therapeutics: Platform Technology Has Potential; Move To Combination Therapy With Opdivo Is NextN/A
2021-11-04 23:17 ESTNewsBicycle Therapeutics gets dosing underway in early-stage BT7480 cancer trialN/A
2021-11-04 23:17 ESTNewsBicycle Therapeutics EPS beats by $0.03, misses on revenueN/A
2021-10-26 09:10 ESTNewsGenentech exercises option for new immuno-oncology program with Bicycle TherapeuticsN/A
2021-10-13 15:17 ESTNewsBicycle Therapeutics prices upsized ADS offering at $54N/A
2021-10-12 18:51 ESTNewsBicycle Therapeutics falls 5% on proposed ADS offeringN/A
2021-10-08 21:15 ESTNewsBicycle Therapeutics draws higher price targets from analysts after cancer study dataN/A
2021-10-08 01:35 ESTNewsBicycle's shares rise as early-stage candidate shows preliminary anti-tumor activity (updated)N/A
2021-08-25 11:00 ESTNewsBicycle Therapeutics: Scaffolding Short Linear Peptides Into BicyclesN/A
2021-08-05 20:10 ESTNewsBicycle Therapeutics EPS misses by $0.02, misses on revenueN/A
2021-07-22 16:37 ESTNewsIonis inks licensing deal with Bicycle Therapeutics to advance LICA technologyN/A
2021-05-07 01:50 ESTNewsBicycle Therapeutics EPS misses by $0.05, beats on revenueN/A
2021-03-18 11:26 ESTAnalyst RatingThe Analyst Target Price has increased from $34.88 to $36.75.Buy
2021-03-13 18:12 ESTFinancialsCompany financials have been released.Neutral
2021-03-12 13:59 ESTEarnings EstimateAn EPS average of -$3.34 is estimated for the 2022 year.Sell
2021-03-12 13:59 ESTEarnings EstimateAn EPS average of -$0.59 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-11 21:22 ESTNewsBicycle Therapeutics EPS misses by $0.32, beats on revenueN/A
2021-01-21 14:38 ESTAnalyst RatingThe Analyst Target Price has increased from $31.38 to $34.88.Buy
2021-01-18 06:16 ESTAnalyst RatingThe Analyst Target Price has increased from $27.75 to $31.38.Buy
2021-01-14 14:35 ESTNewsBicycle Therapeutics gives out pipeline update, shares riseN/A
2020-12-04 19:08 ESTFinancialsCompany financials have been released.Neutral
2020-12-04 10:53 ESTAnalyst RatingThe Analyst Target Price has increased from $27.38 to $27.75.Buy
2020-12-02 13:28 ESTNewsBicycle Therapeutics settles IP dispute with PepscanN/A
2020-11-27 00:34 ESTFinancialsCompany financials have been released.Neutral
2020-11-09 15:35 ESTAnalyst RatingThe Analyst Target Price has decreased from $27.75 to $27.38.Neutral
2020-11-06 23:03 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 10:34 ESTEarnings EstimateAn EPS average of -$0.54 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-06 10:34 ESTAnalyst RatingThe Analyst Target Price has increased from $25.5 to $27.75.Buy

About Bicycle Therapeutics plc (BCYC):

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

See Advanced Chart

General

  • Name Bicycle Therapeutics plc
  • Symbol BCYC
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 87
  • Fiscal Year EndDecember
  • IPO Date2019-05-23
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.bicycletherapeutics.com
View More

Valuation

  • Trailing PE 1839
  • Price/Sales (Trailing 12 Mt.) 52
  • Price/Book (Most Recent Quarter) 6.83
  • Enterprise Value Revenue 51.14
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.92
  • Next Year EPS Estimate -$3.38
  • Next Quarter EPS Estimate -$0.60
  • Operating Margin -500%
  • Return on Assets -24%
  • Return on Equity -54%
  • Revenue 10.39 million
  • Earnings Per Share -$14.16
  • Revenue Per Share $0.54
  • Gross Profit -22759000
  • Quarterly Earnings Growth -27.1%
View More

Highlights

  • Market Capitalization 618.36 million
  • EBITDA -24381000
  • PE Ratio -6.18
  • Analyst Target Price $36.75
  • Book Value Per Share $5.33
View More

Share Statistics

  • Shares Outstanding 23.09 million
  • Shares Float 14.83 million
  • % Held by Insiders 2990%
  • % Held by Institutions 42.85%
  • Shares Short 400080
  • Shares Short Prior Month 397139
  • Short Ratio 2.76
  • Short % of Shares Outstanding 2%
View More

Technicals

  • 52 Week High $33
  • 52 Week Low $10.5
  • 50 Day Moving Average 26.66
  • 200 Day Moving Average 21.57
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Bicycle Therapeutics plc (BCYC) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Bicycle Therapeutics plc (BCYC) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-11$N/A-$0.83-$0.41-101.6%
2020-09-302020-11-05$N/A-$0.52-$0.531.89%
2020-06-302020-08-05$N/A-$0.67-$0.46-45.02%
2020-03-312020-05-07$N/A-$0.63-$0.38-64.36%
2019-12-312020-03-10$5.28 million-$0.25-$0.5251.62%
2019-09-302019-11-07$614000-$0.53-$0.7023.74%
2019-06-302019-08-08$1.52 million-$0.66-$0.62-6.45%
2019-03-312019-05-23$6.38 million-$0.49

Bicycle Therapeutics plc (BCYC) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Bicycle Therapeutics plc (BCYC) Chart:

Bicycle Therapeutics plc (BCYC) News:

Below you will find a list of latest news for Bicycle Therapeutics plc (BCYC) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Bicycle Therapeutics plc (BCYC) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-04-1710CALL0 00TRUE00
2026-04-1720CALL0 00TRUE00
2026-04-1731.6CALL0 100TRUE00
2026-04-1740.45CALL0 150353.23TRUE00
2026-04-1752.35CALL0 100597.45FALSE00
2026-04-1760.5CALL0 221228.35FALSE00
2026-04-1770.38CALL1 67218.68FALSE0.282.8
2026-04-1780CALL0 0783.1FALSE00
2026-04-1790CALL0 0808.69FALSE00
2026-04-17100CALL0 0790.39FALSE00
2026-04-1710PUT0 0380.04FALSE00
2026-04-1720PUT0 01027.75FALSE00
2026-04-1730.05PUT10 20121.05FALSE0.050
2026-04-1740.1PUT0 50580.03FALSE00
2026-04-1750.8PUT0 11596.01TRUE00
2026-04-1760PUT0 0976.57TRUE00
2026-04-1770PUT0 0142.24TRUE00
2026-04-1780PUT0 0170.02TRUE00
2026-04-1790PUT0 0193.32TRUE00
2026-04-17100PUT0 0187.65TRUE00
2026-05-1510CALL0 00TRUE00
2026-05-1520CALL0 00TRUE00
2026-05-1530CALL0 00TRUE00
2026-05-1540CALL0 00TRUE00
2026-05-1552.65CALL0 100333.52FALSE00
2026-05-1560CALL0 01004.44FALSE00
2026-05-1570CALL0 00FALSE00
2026-05-1580CALL0 00FALSE00
2026-05-1590CALL0 00FALSE00
2026-05-15100CALL0 00FALSE00
2026-05-1510PUT0 00FALSE00
2026-05-1520PUT0 00FALSE00
2026-05-1530PUT0 00FALSE00
2026-05-1540.23PUT20 13169.48FALSE-0.12-0.34
2026-05-1550PUT0 01256.63TRUE00
2026-05-1560PUT0 0666.87TRUE00
2026-05-1570PUT0 099.57TRUE00
2026-05-1580PUT0 0104.06TRUE00
2026-05-1590PUT0 0119.53TRUE00
2026-05-15100PUT0 0132.99TRUE00
2026-06-1810CALL0 00TRUE00
2026-06-1820CALL0 00TRUE00
2026-06-1830CALL0 00TRUE00
2026-06-1840.7CALL5 045.67TRUE0.70
2026-06-1851.75CALL0 100FALSE00
2026-06-1860.05CALL0 10165.75FALSE00
2026-06-1872.53CALL0 4252.27FALSE00
2026-06-1880.25CALL0 33209.36FALSE00
2026-06-1890.1CALL0 1030FALSE00
2026-06-18100.1CALL0 2293237.07FALSE00
2026-06-18110.75CALL0 11576.03FALSE00
2026-06-18121.78CALL0 3396.89FALSE00
2026-06-18130CALL0 00FALSE00
2026-06-18140.5CALL0 2480.55FALSE00
2026-06-18150CALL0 0487.37FALSE00
2026-06-18160CALL0 0486.52FALSE00
2026-06-1810PUT0 00FALSE00
2026-06-1820PUT0 00FALSE00
2026-06-1830.1PUT5 65479.18FALSE-0.05-0.33
2026-06-1840.4PUT102 181077.4FALSE-0.03-0.07
2026-06-1851PUT0 23026.99TRUE00
2026-06-1860PUT0 0170.91TRUE00
2026-06-1870PUT0 188.49TRUE00
2026-06-1880PUT0 195.49TRUE00
2026-06-1892.9PUT0 0108.65TRUE00
2026-06-18103.71PUT0 2130.13TRUE00
2026-06-18110PUT0 0130.16TRUE00
2026-06-18120PUT0 0139.23TRUE00
2026-06-18130PUT0 0147.45TRUE00
2026-06-18140PUT0 0154.97TRUE00
2026-06-18150PUT0 0161.92TRUE00
2026-06-18160PUT0 0168.36TRUE00
2026-09-1810CALL0 00TRUE00
2026-09-1820CALL0 00TRUE00
2026-09-1831.6CALL7 2844.8TRUE1.60
2026-09-1840CALL0 00TRUE00
2026-09-1851CALL0 10285.24FALSE00
2026-09-1861.6CALL0 125371.28FALSE00
2026-09-1870CALL0 0308.33FALSE00
2026-09-1880CALL0 00FALSE00
2026-09-1890CALL0 0417.17FALSE00
2026-09-18100CALL0 0241.38FALSE00
2026-09-18110CALL0 00FALSE00
2026-09-18120.35CALL0 1472.49FALSE00
2026-09-18130.35CALL0 119308.56FALSE00
2026-09-1810PUT0 00FALSE00
2026-09-1820PUT0 00FALSE00
2026-09-1830.3PUT0 1264.25FALSE00
2026-09-1840.58PUT102 46471.56FALSE0.580
2026-09-1851.35PUT0 10378.94TRUE00
2026-09-1860PUT0 0121.47TRUE00
2026-09-1870PUT0 089.1TRUE00
2026-09-1880PUT0 077.16TRUE00
2026-09-1890PUT0 072.96TRUE00
2026-09-18100PUT0 081.19TRUE00
2026-09-18110PUT0 088.51TRUE00
2026-09-18120PUT0 095.14TRUE00
2026-09-18130PUT0 0101.2TRUE00

Latest BCYC Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST200$13.335
Jun 13, 2022 7:59 PM EST200$13.335
Jun 13, 2022 7:59 PM EST17$13.33
Jun 13, 2022 7:59 PM EST975$13.3
Jun 13, 2022 7:59 PM EST200$13.36

Bicycle Therapeutics plc (BCYC) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920077995/0001104659-20-077995-index.htm
2020-06-10UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1761612/000000000020005156/0000000000-20-005156-index.htm
2020-09-15SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1761612/000089914020000427/0000899140-20-000427-index.htm
2020-07-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1761612/000092963820000753/0000929638-20-000753-index.htm
2020-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1761612/000104746920002601/0001047469-20-002601-index.htm
2019-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919060061/0001104659-19-060061-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919060805/0001104659-19-060805-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919062674/0001104659-19-062674-index.htm
2019-11-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919065673/0001104659-19-065673-index.htm
2019-12-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919075599/0001104659-19-075599-index.htm
2020-01-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920008696/0001104659-20-008696-index.htm
2020-02-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920010545/0001104659-20-010545-index.htm
2020-02-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920024459/0001104659-20-024459-index.htm
2020-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920027088/0001104659-20-027088-index.htm
2020-03-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920030969/0001104659-20-030969-index.htm
2020-03-10S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920031393/0001104659-20-031393-index.htm
2020-04-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920043974/0001104659-20-043974-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920057711/0001104659-20-057711-index.htm
2020-06-05S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1761612/000110465920070493/0001104659-20-070493-index.htm
2020-06-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1761612/000110465920072426/0001104659-20-072426-index.htm
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920077995/0001104659-20-077995-index.htm
2020-07-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920083108/0001104659-20-083108-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920090550/0001104659-20-090550-index.htm
2020-08-05S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920090870/0001104659-20-090870-index.htm
2020-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920110716/0001104659-20-110716-index.htm
2020-10-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1761612/000110465920111698/0001104659-20-111698-index.htm
2020-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920111705/0001104659-20-111705-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920121565/0001104659-20-121565-index.htm
2019-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119051098/0001209191-19-051098-index.htm
2019-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119051100/0001209191-19-051100-index.htm
2019-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119051101/0001209191-19-051101-index.htm
2019-11-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119055217/0001209191-19-055217-index.htm
2019-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119061400/0001209191-19-061400-index.htm
2020-01-064/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001912/0001209191-20-001912-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001917/0001209191-20-001917-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001921/0001209191-20-001921-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001925/0001209191-20-001925-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001930/0001209191-20-001930-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001944/0001209191-20-001944-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001967/0001209191-20-001967-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001981/0001209191-20-001981-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001990/0001209191-20-001990-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120002003/0001209191-20-002003-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120002011/0001209191-20-002011-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120002019/0001209191-20-002019-index.htm
2020-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120012510/0001209191-20-012510-index.htm
2020-04-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120024640/0001209191-20-024640-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025811/0001209191-20-025811-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025812/0001209191-20-025812-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025813/0001209191-20-025813-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025816/0001209191-20-025816-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025817/0001209191-20-025817-index.htm
2020-08-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120047523/0001209191-20-047523-index.htm
2020-08-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120048252/0001209191-20-048252-index.htm
2020-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1761612/000138713120001831/0001387131-20-001831-index.htm
2020-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000138713120008376/0001387131-20-008376-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1761612/000155837019010277/0001558370-19-010277-index.htm
2020-03-1010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1761612/000155837020002278/0001558370-20-002278-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1761612/000155837020005538/0001558370-20-005538-index.htm
2020-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1761612/000155837020009277/0001558370-20-009277-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1761612/000155837020012697/0001558370-20-012697-index.htm
2020-06-15EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1761612/999999999520001433/9999999995-20-001433-index.htm

Bicycle Therapeutics plc (BCYC) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bicycle Therapeutics plc (BCYC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2990%
Institutional Ownership: 4285%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-04-14Gregory Paul WinterDirectorBuy71,450.00163,927.00https://www.sec.gov/Archives/edgar/data/1761612/000120919120024640/0001209191-20-024640-index.htm